Eptifibatide

Integrilin

Eptifibatide is a cyclic heptapeptide antiplatelet agent, and one of the most striking examples of venom-inspired drug design. Snake venoms contain small proteins called disintegrins that prevent the prey's blood from clotting by blocking platelet aggregation. Eptifibatide is modeled on barbourin, a disintegrin from the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It preserves the key recognition motif that lets it dock onto the platelet surface receptor glycoprotein IIb/IIIa (integrin αIIbβ3). GPIIb/IIIa is the final common pathway of platelet aggregation: when platelets are activated, this receptor changes shape and binds fibrinogen, which cross-links platelets together into a clot. Eptifibatide occupies the receptor and blocks fibrinogen from binding, so platelets cannot clump — regardless of what triggered their activation. This makes it a powerful, reversible inhibitor of clot formation. It is given intravenously, has a rapid onset, and a relatively short duration, with platelet function recovering after the infusion stops. Eptifibatide (Integrilin) is an approved prescription antiplatelet drug used in acute coronary syndromes (such as unstable angina and certain heart attacks) and during percutaneous coronary intervention (PCI, including stenting), typically alongside other anticoagulant and antiplatelet therapy. Its main risk is bleeding, and it can cause thrombocytopenia (a drop in platelet count), so platelet counts and bleeding are monitored. It is cleared substantially by the kidneys, so dosing is reduced in kidney impairment. Eptifibatide is administered in hospital and catheterization-lab settings under specialist care — it is not a self-administered, research, or wellness peptide.